Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Robert B. Ford

Market Cap

185.49 Billion USD

Sector

Healthcare

Website

https://www.abbott.com

Last Update

2/22/2024, 12:00:00 PM

Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

Read More

Overview

Value

22

Growth

62

Health

60

Management

62

Analyst Opinion

91

Total

54

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Has a low level of debt
  • Low risk of bankruptcy
  • Has strong financial health
  • Liked by analysts
  • Has strong dividend growth
  • Very safe dividend

Risk Factors

  • Earnings have declined recently
  • There is a history of diluting shareholders
  • Disliked by Twitter users
  • Price-to-earnings ratio of 35.2 is higher than the market average (19.6x)
  • High preportion of income is paid as dividend

Market Peers

ABT

Key Figures

PE Ratio (TTM)

35.21

Margin Of Safety (DCF)

2.22%

Revenue Growth (5 Year Average)

10.06%

Ratings Consensus

Strong Buy

Share Buybacks

-0.31%

Dividend Yeild (TTM)

1.77%

Valuation

Value Score

22

  • Estimated intrinsic-value of 118.06 USD is higher than current price ( 106.90 USD)
  • Price-to-earnings ratio of 35.2 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 2.52% is worse than the market average (4.7%)
  • Margin-of-safety of 2.22% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 104.4 USD

Current Price: 115.5 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

35.21x

Free Cashflow Yeild

2.52%

PE/Earnings Growth

N/A

Price/Book

5.16x

Growth

Growth Score

62

  • 5 Year Average Earnings growth of 23.23% is higher than the market average (14.48%)
  • 5 Year Average Cashflow growth of 14.04% is higher than the market average (12.35%)
  • 5 Year Average Revenue growth of 10.06% is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • Earnings growth has slowed this year
  • Free Cashflow growth has slowed this year

Revenue Growth

10.06%

Earnings Growth

23.23%

Cashflow Growth

14.04%

Health

Health Score

60

  • Low risk of bankruptcy
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

5.22

Piostroski Score

7.00

Debt/Equity

0.66x

Current Assets/Liabilities

1.63x

Free Cashflow/Total Debt

0.32x

Debt/Capital

0.96x

Dividend

Secure Dividend Score

75

  • Very safe
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 1.77% is less than the market average (1.85%)
  • Long term dividend payout ratio of 113.75% is high and may limit growth
  • Payout ratio (TTM) of 62.14% is higher than the average (40%)
  • Dividend growth has been slowing recently

Dividend Yeild

1.77%

Dividend Growth

3.34%

Payout Ratio (Earnings)

62.14%

Payout Ratio (Cashflow)

70.29%

Management

Management Score

62

  • Has issued new shares to finance growth when share price is high
  • Has returned higher dividends when earnings have risen
  • Return-on-equity of 18.49% is higher than the market average (15%)
  • Return-on-capital-employed of 14.13% is higher than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-0.31%

Recent Buybacks/Dilution

-2.04%

5 Year Price Volitility

23.31%

Return On Assets

9.11%

Return On Capital Employed

14.13%

Return On Equity

18.49%

Return On Free Cashflow

N/A

Return On Investments

643.70%

Social Sentiment

Social Sentiment Score

28

Twitter Sentiment

0.00

Stocktwits Sentiment

56.00

Analysts

Analyst Opinion

91

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Abbott Laboratories

Currency

USD

Beta

0.662568

Vol Avg

4766529

Ceo

Mr. Robert B. Ford

Cik

0000001800

Cusip

002824100

Exchange

New York Stock Exchange

Full Time Employees

115000

Industry

Medical Devices

Sector

Healthcare

Ipo Date

1980-03-17

Address

100 Abbott Park Road

City

North Chicago

State

IL

Country

US

Zip

60064-6400

Phone

224 667 6100

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies